# Treatment approaches for systemic lupus erythematosus
The treatment of severe systemic lupus erythematosus (SLE) is aimed at suppressing the overactive immune response, preventing organ damage and alleviating symptoms. The approach varies depending on the phase of the disease and the organs involved. Below are the main treatment groups described.
---
Corticosteroids
Corticosteroids (such as prednisone or methylprednisolone) have long been the cornerstone of SLE treatment. They suppress inflammatory signals in the immune system and help reduce symptoms more quickly, especially during severe flares or when vital organs are affected.
ProveniIncluded in official guidelines, or approved by EMA or FDA
These medications work by reducing the activity of inflammatory cells and preventing the production of antibodies against the body's own tissues. Known side effects include elevated blood sugar, bone loss (osteoporosis) with long-term use, increased risk of infection, sleep disturbances and weight gain. The goal is usually to keep the dose as low as possible, especially in the long term.
---
Antimalarial drugs
Hydroxychloroquine (and in some cases chloroquine) have been used for SLE for decades. These medications reduce inflammatory activity and prevent flares.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Antimalarial drugs work by suppressing inflammatory molecules in certain immune cells. They are especially helpful for skin and joint manifestations, but also have beneficial effects on long-term disease. Side effects are generally mild: stomach complaints, headaches and sometimes eye problems with long-term use (regular eye checks are recommended).
---
Classical immunosuppressants
In severe SLE, especially when the kidneys are affected (lupus nephritis), medications such as azathioprine, mycophenolate and cyclophosphamide are used.
ProveniIncluded in official guidelines, or approved by EMA or FDA
These substances reduce the multiplication of immune cells. When the kidneys are involved, cyclophosphamide is sometimes administered intravenously in combination with other medications; mycophenolate is an alternative with potentially fewer side effects. Azathioprine helps with maintenance and remission. Possible side effects include infections, anaemia, an increased risk of certain infections (such as herpes zoster), and rarely severe bone marrow toxicity. Patients undergo regular blood tests to monitor safety.
---
Biological agents: anti-B-cell therapy
Rituximab (targeting B cells) and belimumab (targeting BLyS, a substance that sustains B cells) are biological agents that address the immune system in a targeted manner.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Belimumab is specifically approved for SLE and helps prevent flares. It can be given subcutaneously or intravenously. Rituximab is used off-label in some countries for SLE, especially when the kidneys are affected. Both agents reduce harmful antibodies. Side effects can include infections (especially viral infections), reactions at the injection site, and rarely severe immune reactions.
---
Biological agents: other targets
Recent biologics such as anifrolumab (targeting the type I interferon receptor) and dapirolizumab pegol (targeting CD40 ligand) represent newer approaches.
ResearchediPositive results in clinical studies, not yet standard treatment
Anifrolumab is approved in some countries for moderate to severe SLE. These agents intervene at different points in the immune system than classical therapies. Studies show a reduction in flares and improvement in symptoms. Side effects include infections and reactions at the injection site. Long-term data are still being collected.
---
Non-steroidal anti-inflammatory drugs (NSAIDs)
For mild joint and skin manifestations, non-steroidal anti-inflammatory drugs (NSAIDs) can be used.
ProveniIncluded in official guidelines, or approved by EMA or FDA
These medications reduce inflammatory substances and help with pain and swelling. However, they are not suitable for severe SLE or vital organ involvement, and can worsen kidney problems, especially in patients with kidney involvement. Side effects include stomach complaints, intestinal irritation and rarely kidney damage.
---
Treatment of specific organ involvement
Lupus nephritis (kidney involvement)
For kidney damage, cyclophosphamide or mycophenolate is usually used, sometimes in combination with corticosteroids. This is administered intravenously or orally according to a fixed schedule.
ProveniIncluded in official guidelines, or approved by EMA or FDA
This intensive approach is aimed at preventing progression to kidney failure. Side effects depend on the chosen medication.
Nervous system involvement (neurolupus)
For brain or nerve involvement, corticosteroids, immunosuppressants or cyclophosphamide are considered, depending on severity.
ProveniIncluded in official guidelines, or approved by EMA or FDA
The choice depends on the specific involvement (for example, brain inflammation, depression or nerve pain).
Lung involvement
For lung involvement (inflammation, scarring, blood vessels), corticosteroids, mycophenolate or other immunosuppressants may be needed.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Treatment is tailored to the type of lung involvement and its severity.
---
Supportive therapy
Part of the treatment is preventing and treating side effects of the medications themselves.
- **Osteoporosis prevention**: patients who use corticosteroids for a long time sometimes receive calcium supplements and vitamins, and regular bone density checks.
- **Infection prevention**: certain vaccines can be given (outside active flares); anti-infective prophylaxis with certain immunosuppressants.
- **Heart protection**: because SLE increases the risk of heart disease, statins are sometimes prescribed.
---
Ongoing monitoring
Patients undergo regular blood tests (including for kidney function, blood cells and immune markers), urine tests and possibly imaging, to monitor the disease and detect side effects early.
---
Experimental approaches
Currently, in research phases, new targets are being investigated, including those directed against certain inflammatory substances (such as interleukin-17) and signalling molecules. These have not yet found their way into regular practice.
ExperimentaliOngoing in study setting, outcome still unknown
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._